Germany Oncology Drugs Market Analysis

Germany Oncology Drugs Market Executive Summary

The Germany oncology drugs market size is at around $7.19 Bn in 2022 and is projected to reach $15.19 Bn in 2030, exhibiting a CAGR of 9.8% during the forecast period. Germany spends an average of 11.1% of its GDP on healthcare and is one of the European nations with the highest healthcare expenditures. Health spending in Germany hit a record high of $462.96 Bn in the COVID-19 pandemic year of 2020. In Germany, healthcare costs accounted for 13.1% of GDP in 2020 and rose by 1.2% in 2021. Most of the diseases that are prevalent in Germany are comparable to those that are prevalent in other affluent nations. The World Health Organization (WHO) reports that cancer and cardiovascular diseases, including heart attacks and strokes, are the two major causes of fatalities in Germany.

Germany has an age-standardized incidence rate of cancer of roughly 430 cases per 100,000 people. A cancer diagnosis is made in roughly 4.3% of the population each year. The number of incident cases of cancer in 2020 was reported to be 538,140 by the World Cancer Research Fund International.

The oncology drugs market in Germany consists of a wide range of products and services related to the treatment and management of cancer. This includes drugs and medical devices used in cancer diagnosis and treatment, such as imaging equipment and radiation therapy machines. Services include pain management medications and home health care services for cancer patients. The government also plays an active role in the regulation of therapeutics in the oncology segment and excessive pressure on price regulation policies is a challenge among pharmaceutical manufacturers and the country frequently faces a shortage of medicines.

Market Dynamics

Market Growth Drivers

There are several factors that may be driving the market for oncology treatments in Germany. These may include:

• Increasing incidence of cancer: The incidence of cancer is increasing globally, and Germany is no exception. The age-standardized incidence rate of cancer in Germany is about 430 cases per 100,000 population.
• Increasing funding for cancer research: Governments and private organizations are increasing their funding for cancer research, which is expected to drive the development of new treatments and therapies. This, in turn, is expected to drive market growth.
• Increasing adoption of personalized medicine: The use of personalized medicine, which involves tailoring treatment plans to the specific characteristics of each patient's cancer, is increasing in Germany. This trend is expected to drive market growth as personalized medicine can improve treatment outcomes and reduce the risk of adverse effects.

Market Restraints

Some cancer therapies may not be accessible in Germany because they are either undergoing clinical trials or have not received national approval. Due to the extensive regulatory load and requirement for ethical approval, conducting clinical trials in Germany might be difficult. In 2011, the German government introduced an ‘Act on the Reform of the Market for Medicinal Products’ (AMNOG) which aimed at price regulation of cancer drugs that pushed manufacturers to opt out of the market. This created a shortage of medicines. New cancer therapies may take longer to develop as a result. Receiving payment for cancer treatments can be a difficult procedure that not always covers all of the associated costs. In Germany, there have been shortages of several cancer medications, which may have an impact on patient access to care. Branded cancer drug sales may be impacted by the introduction of generic medications to the market.

Competitive Landscape

Key Players

• Eckert & Ziegler BEBIG,
• Oncura Inc.
• GE Healthcare
• Medtronic PLC.
• Varian Medical Systems Inc
• Boehringer Ingelheim (GER)
• Baxter GmbH (GER)
• Daiichi Sankyo Europe GmbH (GER)
• Grifols Deutschland (GER)
• Mundipharma GmbH (GER)
• Pfizer Pharma
• Takeda Pharma

Notable Recent Updates

December 2022 - Pre-Clinical Oncology Program out licensed by MorphoSys - MorphoSys, a pharmaceutical company with headquarters in Germany, announced today that its fully owned subsidiary Constellation Pharmaceuticals, Inc. has signed a global licensing agreement with Novartis to conduct pre-clinical research, develop, and market its novel cancer target inhibitors. Following its purchase of Constellation Pharmaceuticals, Inc., MorphoSys expanded its portfolio of research initiatives by including this one.

August 2022 -To create novel immune-synthetic antibody-drug conjugates, Mersana Therapeutics, and Merck KGaA, Darmstadt, Germany, have announced a research collaboration and commercial license agreement. A leading science and technology company, Merck KGaA, Darmstadt, Germany, operates its biopharmaceuticals business in the United States and Canada as EMD Serono. Guardant Health, Inc. a leading precision oncology company, today announced an expanded collaboration with Merck KGaA to further leverage the GuardantInform Real-World E3vidence (RWE) platform to aid in accelerating development efforts for Merck the expanded strategic partnership will concentrate on developing therapies for key cancer indications with a high unmet need.

January 2021- BeiGene and Novartis $2,200 Mn Deal: Tislelizumab, an anti-PD1 mAb for classical Hodgkin's lymphoma and metastatic urothelial carcinoma, is licensed by Novartis from BeiGene under a contract. In addition to royalties and milestone payments, BeiGene will receive an upfront payment of $650 Mn.

Healthcare Policies and Regulatory Landscape

The Federal Joint Committee (Gemeinsamer Bundesausschuss), a public health agency authorized to establish binding regulations arising out of health reform laws voted by legislators, as well as routine decisions involving healthcare in Germany, regulates the German healthcare system. Promising new cancer research results must be implemented as soon as possible in clinical research and treatment. In order to further this objective, the German Cancer Consortium (DKTK), one of the six German Health Research Centres (DZG), was established in 2012. Germany has a medical regulating organization it is called the Federal Institute for Drugs and Medical Devices (BfArM, or Bundesinstitut für Arzneimittel und Medizinprodukte). The Federal Ministry of Health (BMG) oversees health operations.

Reimbursement Scenario

In Germany, statutory health insurance, which is required for all citizens, typically covers cancer treatment. Chemotherapy, radiation therapy, surgery, and supportive care are only a few of the cancer therapies that are covered by statutory health insurance. The particular coverage, however, may change based on the patient's insurance plan and the type of care being received. Certain therapies need the insurance provider's prior approval. In Germany, purchasing private health insurance is another alternative, which may provide additional cancer treatment coverage as well as coverage for procedures not included in the mandatory health insurance, such as some experimental therapies or complementary therapies. Private insurance plans, however, have more expensive premiums.